Log in to search using one of your social media accounts:


A phase 1/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome

Abstract WT4869 is a synthetic peptide vaccine derived from the Wilms’ tumor gene 1 (WT1) protein. This phase 1/2 open‐label study evaluated the safety and efficacy of WT4869, and biomarkers for response, in patients with myelodysplastic syndrome. WT4869 (5–1200 μg/dose) was administered intradermally every 2 weeks, according to a 3+3 dose‐escalation method in higher‐risk (International Prognostic Scoring System score ≥1.5) or lower‐risk (score
Source: Cancer Science - Category: Cancer & Oncology Authors: Tags: Original Article Source Type: research

Related Links:

More News: Cancer | Cancer & Oncology | Cancer Vaccines | Genetics | Myelodysplastic Syndrome | Pneomococcal Vaccine | Pneumonia | Science | Study | Toxicology | Vaccines